ArticleVaccine2011
Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.
Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Review
- A review of the current anti-New microbes and new infections · 2026Review
- Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV.The Journal of infectious diseases · 2025Article
- A Cryptococcus neoformans polysaccharide conjugate vaccine made with filtered polysaccharide elicits protective immunity in mice.Fungal biology · 2025Article
- Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.Journal of fungi (Basel, Switzerland) · 2024Review
- Semisynthetic Glycoconjugate Vaccine Candidates againstACS infectious diseases · 2024Article
- Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.Archives of microbiology · 2024Review
- Semi-synthetic glycoconjugate vaccine candidate againstbioRxiv : the preprint server for biology · 2024Article
- Antibody Isolation in C. neoformans.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Antibodies to Combat Fungal Infections: Development Strategies and Progress.Microorganisms · 2023Review
- Application of anti-fungal vaccines as a tool against emerging anti-fungal resistance.Frontiers in fungal biology · 2023Review
- Harnessing the Immune Response to Fungal Pathogens for Vaccine Development.Annual review of microbiology · 2022Review
- Adjuvant Curdlan Contributes to Immunization againstVaccines · 2022Article
- A glycan FRET assay for detection and characterization of catalytic antibodies to theProceedings of the National Academy of Sciences of the United States of America · 2021Article
- A synthetic glycan array containingChemical science · 2020Article
- Peeling the onion: the outer layers of Cryptococcus neoformans.Memorias do Instituto Oswaldo Cruz · 2018Review
- Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.PloS one · 2016Article
- Exploiting fungal cell wall components in vaccines.Seminars in immunopathology · 2015Review
- Killed Saccharomyces cerevisiae protects against lethal challenge of Cryptococcus grubii.Mycopathologia · 2014Article
- Vaccine immunity against fungal infections.Current opinion in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Galactoxylomannan (GalXM) is a complex polysaccharide produced by the human pathogenic fungus Cryptococcus neoformans that mediates profound immunological derangements in murine models. GalXM is essentially non-immunogenic and produces immune paralysis in mice. Previous studies have attempted to enhance immunogenicity by conjugating GalXM to a protein carrier, but only transient antibody responses were elicited. Here we report the generation of two GalXM conjugates with bovine serum albumin (BSA) and protective antigen (PA) of Bacillus anthracis, respectively, using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) as the cyanylating reagent. Both conjugates induced potent and sustained antibody responses as detected by both cross antigen-based and CovaLink direct ELISAs. We confirmed the specificity of the response to GalXM by inhibition ELISA and immunofluorescence. The isotype composition analysis revealed that IgG and IgM were abundant in the immune sera against GalXM, consistent with the induction of a T cell-dependent response. IgG1 was the predominant IgG subclass against GalXM, while immunization with Quil A as adjuvant elicited a significantly higher production of IgG2a than with Freund's adjuvant. Immune sera were not opsonic for C. neoformans and there was no survival difference between immune and non-immune mice challenged with C. neoformans. These results demonstrated the effectiveness of the GalXM-protein conjugate to induce robust immune responses although no evidence was obtained that such responses contributed to host defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.